A Phase 2 interventional study of Pembrolizumab and Favezelimab in Advanced Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 81 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with quavonlimab (MK-1308), favezelimab (MK-4280), or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either quavonlimab, favezelimab, or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with low GEP and high TMB, 3) greater than 20% among participants with high GEP and low TMB, and 4) greater than 45% among participants with high GEP and high TMB.
After Amendment 5, participants can receive 800 mg of favezelimab every 3 weeks (Q3W)
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received pembrolizumab 200 mg every 3 weeks (Q3W) intravenously (IV) plus lenvatinib 20 mg orally once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
Biological: Pembrolizumab · Drug: Lenvatinib
Participants received pembrolizumab 200 mg Q3W IV plus quavonlimab 25 mg every 6 weeks (Q6W) IV until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Biological: Pembrolizumab · Drug: Quavonlimab
Participants received pembrolizumab 200 mg Q3W IV plus favezelimab 200 mg Q3W IV until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Biological: Pembrolizumab · Biological: Favezelimab
Participants received pembrolizumab 200 mg Q3W IV plus favezelimab 800 mg Q3W IV until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
Biological: Pembrolizumab · Biological: Favezelimab
200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Also known as: MK-3475
200 mg or 800 mg favezelimab solution for IV infusion administered Q3W
Also known as: MK-4280
20 mg lenvatinib capsules administered orally once daily
Also known as: MK-7902
Quavonlimab solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
Also known as: MK-1308
Objective Response Rate (ORR)
ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by local site radiologic review. The percentage of participants who experience CR or PR as assessed by local site radiologic review with confirmatory assessment per RECIST 1.1 is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.
Time frame: Up to approximately 80 months
Progression Free Survival (PFS)
PFS was defined as the time from allocation to the first documented progressive disease (PD) or death due to any cause, whichever occurs first according to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by local site radiologic review. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS for all participants is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.
Time frame: Up to approximately 80 months
Overall Survival (OS)
OS was defined as the time from the date of allocation to death due to any cause. The OS for all participants is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.
Time frame: Up to approximately 80 months
Number of Participants Experiencing Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm experiencing an AE is reported.
Time frame: Up to approximately 80 months
Number of Participants Discontinuing Study Drug Due to AEs
An AE was defined as any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm that discontinued study drug due to an AE is reported.
Time frame: Up to approximately 39 months
| Milestone | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg |
|---|---|---|---|---|
| Started | 81 | 83 | 30 | 51 |
| Treated | 80 | 82 | 30 | 51 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 81 | 83 | 30 | 51 |
| Withdrew: Withdrawal by subject | 2 | 5 | 0 | 3 |
| Withdrew: Sponsor decision | 9 | 16 | 5 | 12 |
| Withdrew: Randomized by mistake without study treatment | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Death | 69 | 61 | 25 | 34 |
ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline sum diameters) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by local site radiologic review. The percentage of participants who experience CR or PR as assessed by local site radiologic review with confirmatory assessment per RECIST 1.1 is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.
| Percentage of Participants | Pembrolizumab + Lenvatinib - GEP Low / TMB Low | Pembrolizumab + Lenvatinib - GEP Low / TMB High | Pembrolizumab + Lenvatinib - GEP High / TMB Low | Pembrolizumab + Lenvatinib - GEP High / TMB High | Pembrolizumab + Quavonlimab - GEP Low / TMB Low | Pembrolizumab + Quavonlimab - GEP Low / TMB High | Pembrolizumab + Quavonlimab - GEP High / TMB Low | Pembrolizumab + Quavonlimab - GEP High / TMB High | Pembrolizumab + Favezelimab 200 mg - GEP Low / TMB Low | Pembrolizumab + Favezelimab 200 mg - GEP Low / TMB High | Pembrolizumab + Favezelimab 200 mg - GEP High / TMB Low | Pembrolizumab + Favezelimab 200 mg - GEP High / TMB High | Pembrolizumab + Favezelimab 800 mg - GEP Low / TMB High | Pembrolizumab + Favezelimab 800 mg - GEP High / TMB Low | Pembrolizumab + Favezelimab 800 mg - GEP High / TMB High |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 12.0 (2.5 to 31.2) | 33.3 (9.9 to 65.1) | 40.9 (20.7 to 63.6) | 57.1 (34.0 to 78.2) | 11.5 (2.4 to 30.2) | 30.8 (9.1 to 61.4) | 13.6 (2.9 to 34.9) | 52.4 (29.8 to 74.3) | 0.0 (0.0 to 28.5) | 33.3 (4.3 to 77.7) | 25.0 (3.2 to 65.1) | 60.0 (14.7 to 94.7) | 27.3 (6.0 to 61.0) | 13.6 (2.9 to 34.9) | 50.0 (26.0 to 74.0) |
PFS was defined as the time from allocation to the first documented progressive disease (PD) or death due to any cause, whichever occurs first according to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by local site radiologic review. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The PFS for all participants is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.
| Months | Pembrolizumab + Lenvatinib - GEP Low / TMB Low | Pembrolizumab + Lenvatinib - GEP Low / TMB High | Pembrolizumab + Lenvatinib - GEP High / TMB Low | Pembrolizumab + Lenvatinib - GEP High / TMB High | Pembrolizumab + Quavonlimab - GEP Low / TMB Low | Pembrolizumab + Quavonlimab - GEP Low / TMB High | Pembrolizumab + Quavonlimab - GEP High / TMB Low | Pembrolizumab + Quavonlimab - GEP High / TMB High | Pembrolizumab + Favezelimab 200 mg - GEP Low / TMB Low | Pembrolizumab + Favezelimab 200 mg - GEP Low / TMB High | Pembrolizumab + Favezelimab 200 mg - GEP High / TMB Low | Pembrolizumab + Favezelimab 200 mg - GEP High / TMB High | Pembrolizumab + Favezelimab 800 mg - GEP Low / TMB High | Pembrolizumab + Favezelimab 800 mg - GEP High / TMB Low | Pembrolizumab + Favezelimab 800 mg - GEP High / TMB High |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 5.4 (2.3 to 8.8) | 13.8 (1.5 to 19.4) | 8.2 (4.2 to 19.7) | 17.8 (6.0 to 20.7) | 2.8 (2.0 to 6.0) | 3.9 (1.9 to 17.3) | 6.1 (2.1 to 12.8) | 17.0 (9.3 to 29.1) | 2.1 (1.9 to 2.1) | 8.1 (1.7 to NA) | 2.1 (0.9 to 6.5) | 6.3 (0.4 to NA) | 4.2 (1.8 to 12.2) | 3.5 (2.0 to 8.2) | 20.2 (6.1 to NA) |
OS was defined as the time from the date of allocation to death due to any cause. The OS for all participants is presented. Participants were assigned to 1 of 4 biomarker-defined groups (GEP low/TMB low, GEP low/TMB high, GEP high/TMB low, and GEP high/TMB high) and randomized within-group to receive a combination treatment of study interventions. Per protocol, no participants within GEP Low/TMB Low biomarker group were assigned to receive Pembrolizumab + Favezelimab 800 mg.
| Months | Pembrolizumab + Lenvatinib - GEP Low / TMB Low | Pembrolizumab + Lenvatinib - GEP Low / TMB High | Pembrolizumab + Lenvatinib - GEP High / TMB Low | Pembrolizumab + Lenvatinib - GEP High / TMB High | Pembrolizumab + Quavonlimab - GEP Low / TMB Low | Pembrolizumab + Quavonlimab - GEP Low / TMB High | Pembrolizumab + Quavonlimab - GEP High / TMB Low | Pembrolizumab + Quavonlimab - GEP High / TMB High | Pembrolizumab + Favezelimab 200 mg - GEP Low / TMB Low | Pembrolizumab + Favezelimab 200 mg - GEP Low / TMB High | Pembrolizumab + Favezelimab 200 mg - GEP High / TMB Low | Pembrolizumab + Favezelimab 200 mg - GEP High / TMB High | Pembrolizumab + Favezelimab 800 mg - GEP Low / TMB High | Pembrolizumab + Favezelimab 800 mg - GEP High / TMB Low | Pembrolizumab + Favezelimab 800 mg - GEP High / TMB High |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) | 16.0 (5.4 to 20.2) | 16.9 (3.8 to 33.2) | 22.5 (12.0 to 41.3) | 22.7 (16.9 to 56.0) | 13.3 (8.4 to 20.0) | 20.1 (7.7 to NA) | 23.7 (7.9 to 43.1) | 51.6 (17.6 to NA) | 8.6 (3.8 to 35.4) | 20.8 (1.7 to NA) | 12.6 (0.9 to 25.4) | NA (13.5 to NA) | 18.6 (3.4 to 41.2) | 11.1 (5.2 to 19.6) | NA (13.0 to NA) |
An AE was defined as any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm experiencing an AE is reported.
| Participants | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg |
|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 79 | 78 | 27 | 49 |
An AE was defined as any untoward medical occurrence in participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. The number of participants in each treatment arm that discontinued study drug due to an AE is reported.
| Participants | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg |
|---|---|---|---|---|
| Number of Participants Discontinuing Study Drug Due to AEs | 34 | 18 | 4 | 15 |
Collected over Up to approximately 80 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pembrolizumab + Lenvatinib | 71/81 (87.7%) | 42/80 (52.5%) | 76/80 (95%) |
| Pembrolizumab + Quavonlimab | 63/83 (75.9%) | 39/82 (47.6%) | 75/82 (91.5%) |
| Pembrolizumab + Favezelimab 200 mg | 25/30 (83.3%) | 14/30 (46.7%) | 25/30 (83.3%) |
| Pembrolizumab + Favezelimab 800 mg | 36/51 (70.6%) | 31/51 (60.8%) | 47/51 (92.2%) |
| Event | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 6/80 | 6/82 | 2/30 | 4/51 |
| Ischaemic strokeNervous system disorders | 0/80 | 0/82 | 2/30 | 0/51 |
| Myocardial infarctionCardiac disorders | 5/80 | 0/82 | 0/30 | 0/51 |
| Pericardial effusionCardiac disorders | 0/80 | 0/82 | 0/30 | 3/51 |
| COVID-19Infections and infestations | 0/80 | 3/82 | 0/30 | 3/51 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/80 | 3/82 | 1/30 | 3/51 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/80 | 2/82 | 0/30 | 3/51 |
| COVID-19 pneumoniaInfections and infestations | 3/80 | 1/82 | 0/30 | 2/51 |
| HyponatraemiaMetabolism and nutrition disorders | 1/80 | 1/82 | 1/30 | 2/51 |
| DiarrhoeaGastrointestinal disorders | 3/80 | 1/82 | 1/30 | 1/51 |
| Event | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg |
|---|---|---|---|---|
| HypertensionVascular disorders | 42/80 | 4/82 | 1/30 | 3/51 |
| DiarrhoeaGastrointestinal disorders | 36/80 | 16/82 | 3/30 | 15/51 |
| HypothyroidismEndocrine disorders | 29/80 | 7/82 | 4/30 | 10/51 |
| Decreased appetiteMetabolism and nutrition disorders | 27/80 | 15/82 | 6/30 | 7/51 |
| AstheniaGeneral disorders | 26/80 | 11/82 | 4/30 | 6/51 |
| FatigueGeneral disorders | 26/80 | 17/82 | 1/30 | 11/51 |
| PruritusSkin and subcutaneous tissue disorders | 12/80 | 24/82 | 6/30 | 9/51 |
| ConstipationGastrointestinal disorders | 23/80 | 9/82 | 6/30 | 6/51 |
| NauseaGastrointestinal disorders | 22/80 | 13/82 | 4/30 | 8/51 |
| StomatitisGastrointestinal disorders | 22/80 | 5/82 | 0/30 | 1/51 |
| Age, Continuous(Years) | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg | Total |
|---|---|---|---|---|---|
| Mean | 65.4 ± 9.4 | 67.3 ± 9.7 | 62.4 ± 10.1 | 67.9 ± 8.4 | 66.2 ± 9.5 |
| Sex: Female, Male(Participants) | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg | Total |
|---|---|---|---|---|---|
| Female | 31 | 30 | 9 | 15 | 85 |
| Male | 50 | 53 | 21 | 36 | 160 |
| Ethnicity (NIH/OMB)(Participants) | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 3 | 0 | 7 |
| Not Hispanic or Latino | 76 | 79 | 27 | 48 | 230 |
| Unknown or Not Reported | 3 | 2 | 0 | 3 | 8 |
| Race (NIH/OMB)(Participants) | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 22 | 25 | 8 | 19 | 74 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 0 | 0 | 4 |
| White | 56 | 52 | 21 | 31 | 160 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 1 | 1 | 6 |
| Biomarker Defined Subgroups(Participants) | Pembrolizumab + Lenvatinib | Pembrolizumab + Quavonlimab | Pembrolizumab + Favezelimab 200 mg | Pembrolizumab + Favezelimab 800 mg | Total |
|---|---|---|---|---|---|
| GEP Low / TMB Low | 25 | 26 | 11 | 0 | 62 |
| GEP Low / TMB High | 13 | 13 | 6 | 11 | 43 |
| GEP High / TMB Low | 22 | 22 | 8 | 22 | 74 |
| GEP High / TMB High | 21 | 22 | 5 | 18 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Oct 2018 to primary completion in Jun 2025, 80 months.
Results were first posted in Jun 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Favezelimab · Lenvatinib · Quavonlimab
Parkinson Disease 4, Autosomal Dominant Lewy Body